Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MEDI0382 in Overweight/Obese T2DM
NCT03244800Phase 2Completed
- Sponsor
- MedImmune
- Start
- Sep 2017
- Primary completion
- Jan 2018
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of cotadutide in type 2 diabetes mellitus (T2DM) and obesity (4 cohorts), sponsored by MedImmune. Primary endpoints: Percent Change From Baseline in Plasma Glucose Area Under the Concentration-time Curve From Time 0 to 4 Hours and Percent Change From Baseline in Body Weight at Day 50. Started Sep 2017; status: completed.
02
Drugs
cotadutide
03
Conditions
type 2 diabetes mellitus (T2DM)obesity
Beyond the preview
Go deeper on NCT03244800.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03244800.